Background:We investigated the role of pharmacists in adverse event (AE) management during renal cell carcinoma (RCC) drug therapy by surveying patients, physicians, and pharmacists. We identified the types of AEs for which pharmacist involvement is beneficial and explored measures to promote pharmacist intervention.Methods:This was an ad hoc analysis of a questionnaire-based cross-sectional web survey conducted from May to June 2022 among patients undergoing RCC drug therapy, physicians prescribing RCC treatments, and pharmacists involved in oncology care in Japan.Results:A total of 83 patients with metastatic RCC, 165 physicians, and 218 pharmacists were included. Among patients, 28.9% reported experiencing AEs or symptoms requiring pharmacist intervention. Most physicians (78.2%) and pharmacists (96.3%) supported pharmacist involvement in AE management. Notably, 35.6% of patients who reported no AEs or symptoms requiring pharmacist intervention acknowledged difficulty in communicating AEs to their physicians. Regarding desired pharmacist interventions for AEs, patients prioritized rash/pruritus, fatigue, and diarrhea; physicians emphasized stomatitis and anorexia; pharmacists identified constipation, stomatitis, and diarrhea. The most common reason patients valued pharmacist involvement was the reassurance of support from multiple healthcare providers. Physicians and pharmacists valued pharmacists’ greater familiarity with AE management, particularly considering physicians’ limited time. Raising awareness among patients and healthcare professionals, patient requests, and improving institutional support were strategies to enhance pharmacist involvement. Over 86% of healthcare professionals considered pharmaceutical outpatient clinics necessary to strengthen interdisciplinary collaboration.Conclusions:This study highlights widespread support among patients, physicians, and pharmacists for pharmacist involvement in managing AEs during RCC drug therapy.
背景：本研究通过调查患者、医师及药师，探讨了药师在肾细胞癌药物治疗期间不良事件管理中的作用。我们明确了药师参与有益的不良事件类型，并探索了促进药师干预的措施。 方法：本研究为一项基于问卷的横断面网络调查的专项分析，于2022年5月至6月期间在日本接受肾细胞癌药物治疗的患者、开具肾细胞癌治疗处方的医师以及参与肿瘤治疗的药师中进行。 结果：共纳入83例转移性肾细胞癌患者、165名医师和218名药师。28.9%的患者报告经历过需要药师干预的不良事件或症状。大多数医师（78.2%）和药师（96.3%）支持药师参与不良事件管理。值得注意的是，在报告无需要药师干预的不良事件或症状的患者中，35.6%承认难以向医师沟通不良事件。关于期望药师干预的不良事件，患者优先关注皮疹/瘙痒、疲劳和腹泻；医师强调口腔炎和厌食；药师则关注便秘、口腔炎和腹泻。患者重视药师参与的最常见原因是获得来自多位医疗专业人员的支持保障。医师和药师看重药师对不良事件管理更为熟悉，特别是考虑到医师时间有限。提高患者和医疗专业人员意识、患者主动要求以及改善机构支持是增强药师参与的策略。超过86%的医疗专业人员认为有必要设立药学门诊以加强跨学科协作。 结论：本研究显示患者、医师和药师普遍支持药师参与肾细胞癌药物治疗期间的不良事件管理。
肿瘤(癌症)患者之家